Developer docs
API playgroundTry for free, no card

Search company profiles

Escient Pharmaceuticals

Full company profile

uuid0002waq

Namestring
Escient Pharmaceuticals
Legal namestring
Escient Pharmaceuticals Inc
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Escient Pharmaceuticals was a clinical-stage biotechnology company founded in 2017 and headquartered in San Diego, California, focused on developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company built its pipeline around the unmet needs of patients with mast cell-mediated disorders and severe pruritus conditions, including chronic inducible urticaria, chronic spontaneous urticaria, atopic dermatitis, and cholestatic/uremic pruritus associated with primary biliary cholangitis, primary sclerosing cholangitis, and chronic kidney disease. The company served these patient populations through clinical-stage drug development rather than commercial sales.

The core technology centered on an industry-leading MRGPR platform combining proprietary genetic models, GPCR-focused pharmacology, and medicinal chemistry capabilities. The lead clinical programs were EP262, a once-daily oral MRGPRX2 antagonist for mast cell-mediated diseases that blocks IgE-independent mast cell activation, and EP547, an oral MRGPRX4 antagonist that blocks bile acid-, bilirubin-, and urobilin-driven pruritus signaling. Both candidates were wholly-owned, first-in-class, and supported by Phase 1 safety and pharmacokinetic data; additional discovery-stage programs targeted MRGPRD and MRGPRX1.

Escient operated as a pre-revenue, venture-backed biotech with no commercial products and no disclosed pricing. The business model relied on advancing candidates through clinical milestones to create exit value through M&A or partnership rather than independent commercialization. The company raised approximately $237.5 million across three disclosed financing rounds from top-tier life science investors including NEA, Abingworth, The Column Group, 5AM Ventures, and Sanofi Ventures. In May 2024, Incyte Corporation completed its acquisition of Escient for $750 million plus net cash, transferring EP262 and EP547 into Incyte's Inflammation and Autoimmunity portfolio.

Short descriptiontext

Escient Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) for mast cell-mediated disorders and pruritus conditions. Acquired by Incyte in May 2024 for $750 million plus net cash.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, small molecule therapeutics, GPCR drug discovery, MRGPR antagonists, neurosensory-inflammatory disorders
Industry1 code
PRIMARYHLAKAAAH
Mast Cell Disorders Specialty Care
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of novel therapeutics following regulatory approval. The company was acquired by Incyte for $750 million in May 2024, indicating successful exit strategy through M&A rather than independent commercialization.

escientpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Escient Pharmaceuticals develops first-in-class, oral small molecule therapeutics that antagonize Mas-related G protein-coupled receptors (MRGPRs) for the treatment of mast cell-mediated and pruritic disorders. Its lead candidates, EP262 (MRGPRX2 antagonist) and EP547 (MRGPRX4 antagonist), are being advanced for chronic urticaria, atopic dermatitis, and cholestatic/uremic pruritus, supported by an in-house MRGPR-focused drug discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EP262 Phase 1 study (64 healthy volunteers): safe and well-tolerated at all doses with no serious adverse events, no adverse events leading to discontinuation, and no clinically meaningful changes in safety parameters
+3 more records
Product overview1 text field

Escient Pharmaceuticals is a clinical-stage biotechnology company developing a pipeline of first-in-class, oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company's lead product candidates include EP262 (MRGPRX2 antagonist) for mast cell-mediated disorders such as chronic urticaria and atopic dermatitis, and EP547 (MRGPRX4 antagonist) for cholestatic and uremic pruritus. All programs are wholly-owned and the company was acquired by Incyte in May 2024.

Product and service4 records
1EP262 (MRGPRX2 Antagonist)
CategoryClinical Program — Small Molecule Therapeutic
Description

Potent, highly selective, once-daily oral small molecule antagonist of MRGPRX2 for the potential treatment of mast cell-mediated diseases including chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), and atopic dermatitis; designed to block IgE-independent mast cell activation.

2EP547 (MRGPRX4 Antagonist)
CategoryClinical Program — Small Molecule Therapeutic
Description

Potent, highly selective antagonist that blocks MRGPRX4 activation by bile acids, bilirubin, and urobilin for the potential treatment of cholestatic and uremic pruritus, offering a disease-specific oral alternative to non-specific pruritus therapies.

3MRGPRD Program
CategoryDiscovery Program — Small Molecule Therapeutic
Description

Early-stage discovery program targeting the MRGPRD receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.

4MRGPRX1 Program
CategoryDiscovery Program — Small Molecule Therapeutic
Description

Early-stage discovery program targeting the MRGPRX1 receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Incyte acquired Escient Pharmaceuticals in May 2024 for $750 million plus net cash. The acquisition strengthens Incyte's Inflammation and Autoimmunity (IAI) pipeline with EP262 and EP547, first-in-class oral MRGPR antagonists.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developing remibrutinib, an oral TYK2 inhibitor in Phase 3 for chronic spontaneous urticaria — the same indication as Escient's EP262, making it the most direct oral competitor in IgE-independent CSU treatment.

TypeDirect peer
Description

Clinical-stage biotech focused on pruritus therapeutics (KORSUVA/difelikefalin for uremic and cholestatic pruritus), directly competing with EP547 in the same disease settings and pursuing oral alternative formulations.

3Allakos Inc.
TypeDirect peer
Description

Developed anti-Siglec-8 antibody lirentelimab for chronic spontaneous urticaria and other mast cell/eosinophil-driven diseases, overlapping with EP262's IgE-independent mast cell approach.

TypeDirect peer
Description

Clinical-stage immunology and dermatology company developing oral small molecules (including MRGPRX2 antagonists such as EVO756) for chronic spontaneous urticaria, directly paralleling Escient's EP262 program.

TypeDirect peer
Description

Dermatology-focused biotech commercializing topical roflumilast (ZORYVE) for atopic dermatitis and seborrheic dermatitis, sharing atopic dermatitis and pruritus indications with Escient's EP262/EP547.

TypeDirect peer
Description

Dermatology-focused company developing topical tapinarof (VTAMA) for atopic dermatitis and other inflammatory skin diseases, overlapping commercially with EP262's atopic dermatitis indication.

TypeBroad incumbent
Description

Co-developer (with Sanofi) of DUPIXENT (dupilumab), the leading biologic for atopic dermatitis and now chronic spontaneous urticaria — the dominant large-molecule competitor to Escient's EP262 across both indications.

TypeBroad incumbent
Description

Commercializes DUPIXENT (dupilumab) with Regeneron in atopic dermatitis and chronic spontaneous urticaria, and was an Escient investor via Sanofi Ventures — a key strategic incumbent in the same therapeutic indications.

TypeBroad incumbent
Description

Acquired Escient in May 2024 for $750M plus net cash and now owns EP262/EP547 as part of its Inflammation and Autoimmunity franchise, alongside broader commercial dermatology/allergy assets including ruxolitinib cream (OPZELURA).

TypeBroad incumbent
Description

Global dermatology-focused pharmaceutical company with a broad portfolio in atopic dermatitis (e.g., nemolizumab), inflammatory skin conditions, and pruritus — overlapping with EP262/EP547 indications at a broader commercial scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Escient Pharmaceuticals

Clinical-Stage Biopharmaceuticalsescientpharma.com

Escient Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) for mast cell-mediated disorders and pruritus conditions. Acquired by Incyte in May 2024 for $750 million plus net cash.

What Escient Pharmaceuticals does

Escient Pharmaceuticals was a clinical-stage biotechnology company founded in 2017 and headquartered in San Diego, California, focused on developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company built its pipeline around the unmet needs of patients with mast cell-mediated disorders and severe pruritus conditions, including chronic inducible urticaria, chronic spontaneous urticaria, atopic dermatitis, and cholestatic/uremic pruritus associated with primary biliary cholangitis, primary sclerosing cholangitis, and chronic kidney disease. The company served these patient populations through clinical-stage drug development rather than commercial sales.

The core technology centered on an industry-leading MRGPR platform combining proprietary genetic models, GPCR-focused pharmacology, and medicinal chemistry capabilities. The lead clinical programs were EP262, a once-daily oral MRGPRX2 antagonist for mast cell-mediated diseases that blocks IgE-independent mast cell activation, and EP547, an oral MRGPRX4 antagonist that blocks bile acid-, bilirubin-, and urobilin-driven pruritus signaling. Both candidates were wholly-owned, first-in-class, and supported by Phase 1 safety and pharmacokinetic data; additional discovery-stage programs targeted MRGPRD and MRGPRX1.

Escient operated as a pre-revenue, venture-backed biotech with no commercial products and no disclosed pricing. The business model relied on advancing candidates through clinical milestones to create exit value through M&A or partnership rather than independent commercialization. The company raised approximately $237.5 million across three disclosed financing rounds from top-tier life science investors including NEA, Abingworth, The Column Group, 5AM Ventures, and Sanofi Ventures. In May 2024, Incyte Corporation completed its acquisition of Escient for $750 million plus net cash, transferring EP262 and EP547 into Incyte's Inflammation and Autoimmunity portfolio.

Escient Pharmaceuticals firmographics

Firmographics
Name
Escient Pharmaceuticals
Legal name
Escient Pharmaceuticals Inc
Website
https://escientpharma.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Escient Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) for mast cell-mediated disorders and pruritus conditions. Acquired by Incyte in May 2024 for $750 million plus net cash.
Ownership category
akta.pro rank

Escient Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAAAH
Mast Cell Disorders Specialty Care

Keywords

  • Clinical-stage biotechnology
  • Small molecule therapeutics
  • GPCR drug discovery
  • MRGPR antagonists
  • Neurosensory-inflammatory disorders

Where Escient Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Escient Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of novel therapeutics following regulatory approval. The company was acquired by Incyte for $750 million in May 2024, indicating successful exit strategy through M&A rather than independent commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Escient Pharmaceuticals product offering

Product offering

Core offering

Escient Pharmaceuticals develops first-in-class, oral small molecule therapeutics that antagonize Mas-related G protein-coupled receptors (MRGPRs) for the treatment of mast cell-mediated and pruritic disorders. Its lead candidates, EP262 (MRGPRX2 antagonist) and EP547 (MRGPRX4 antagonist), are being advanced for chronic urticaria, atopic dermatitis, and cholestatic/uremic pruritus, supported by an in-house MRGPR-focused drug discovery platform.

Product overview

Escient Pharmaceuticals is a clinical-stage biotechnology company developing a pipeline of first-in-class, oral small molecule therapeutics targeting Mas-related G protein-coupled receptors (MRGPRs) along the neurosensory-inflammatory axis. The company's lead product candidates include EP262 (MRGPRX2 antagonist) for mast cell-mediated disorders such as chronic urticaria and atopic dermatitis, and EP547 (MRGPRX4 antagonist) for cholestatic and uremic pruritus. All programs are wholly-owned and the company was acquired by Incyte in May 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • EP262 (MRGPRX2 Antagonist) Potent, highly selective, once-daily oral small molecule antagonist of MRGPRX2 for the potential treatment of mast cell-mediated diseases including chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), and atopic dermatitis; designed to block IgE-independent mast cell activation.
  • EP547 (MRGPRX4 Antagonist) Potent, highly selective antagonist that blocks MRGPRX4 activation by bile acids, bilirubin, and urobilin for the potential treatment of cholestatic and uremic pruritus, offering a disease-specific oral alternative to non-specific pruritus therapies.
  • MRGPRD Program Early-stage discovery program targeting the MRGPRD receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.
  • MRGPRX1 Program Early-stage discovery program targeting the MRGPRX1 receptor as part of Escient's broader MRGPR-focused neurosensory-inflammatory pipeline; specific indication undisclosed.

Quantifiable outcome

  • EP262 Phase 1 study (64 healthy volunteers): safe and well-tolerated at all doses with no serious adverse events, no adverse events leading to discontinuation, and no clinically meaningful changes in safety parameters
  • +3 more outcomes

Companies that use Escient Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

Escient Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Escient Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Incyte CorporationcoreStrategic or Co-development PartnerIncyte acquired Escient Pharmaceuticals in May 2024 for $750 million plus net cash. The acquisition strengthens Incyte's Inflammation and Autoimmunity (IAI) pipeline with EP262 and EP547, first-in-class oral MRGPR antagonists.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Escient Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Novartis: Developing remibrutinib, an oral TYK2 inhibitor in Phase 3 for chronic spontaneous urticaria — the same indication as Escient's EP262, making it the most direct oral competitor in IgE-independent CSU treatment.
  • Cara Therapeutics: Clinical-stage biotech focused on pruritus therapeutics (KORSUVA/difelikefalin for uremic and cholestatic pruritus), directly competing with EP547 in the same disease settings and pursuing oral alternative formulations.
  • Allakos Inc. Developed anti-Siglec-8 antibody lirentelimab for chronic spontaneous urticaria and other mast cell/eosinophil-driven diseases, overlapping with EP262's IgE-independent mast cell approach.
  • Evommune Inc. Clinical-stage immunology and dermatology company developing oral small molecules (including MRGPRX2 antagonists such as EVO756) for chronic spontaneous urticaria, directly paralleling Escient's EP262 program.
  • Arcutis Biotherapeutics: Dermatology-focused biotech commercializing topical roflumilast (ZORYVE) for atopic dermatitis and seborrheic dermatitis, sharing atopic dermatitis and pruritus indications with Escient's EP262/EP547.
  • Dermavant Sciences: Dermatology-focused company developing topical tapinarof (VTAMA) for atopic dermatitis and other inflammatory skin diseases, overlapping commercially with EP262's atopic dermatitis indication.

Broad incumbents

  • Regeneron Pharmaceuticals: Co-developer (with Sanofi) of DUPIXENT (dupilumab), the leading biologic for atopic dermatitis and now chronic spontaneous urticaria — the dominant large-molecule competitor to Escient's EP262 across both indications.
  • Sanofi: Commercializes DUPIXENT (dupilumab) with Regeneron in atopic dermatitis and chronic spontaneous urticaria, and was an Escient investor via Sanofi Ventures — a key strategic incumbent in the same therapeutic indications.
  • Incyte Corporation: Acquired Escient in May 2024 for $750M plus net cash and now owns EP262/EP547 as part of its Inflammation and Autoimmunity franchise, alongside broader commercial dermatology/allergy assets including ruxolitinib cream (OPZELURA).
  • Galderma: Global dermatology-focused pharmaceutical company with a broad portfolio in atopic dermatitis (e.g., nemolizumab), inflammatory skin conditions, and pruritus — overlapping with EP262/EP547 indications at a broader commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Escient Pharmaceuticals social profiles

Digital presence

Escient Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Escient Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

Escient Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Escient Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Escient Pharmaceuticals

What does Escient Pharmaceuticals do?

Escient Pharmaceuticals develops first-in-class, oral small molecule therapeutics that antagonize Mas-related G protein-coupled receptors (MRGPRs) for the treatment of mast cell-mediated and pruritic disorders. Its lead candidates, EP262 (MRGPRX2 antagonist) and EP547 (MRGPRX4 antagonist), are being advanced for chronic urticaria, atopic dermatitis, and cholestatic/uremic pruritus, supported by an in-house MRGPR-focused drug discovery platform.

Is Escient Pharmaceuticals a public or private company?

Escient Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.

When was Escient Pharmaceuticals founded?

Escient Pharmaceuticals was founded in 2017. It employs 11 to 50 people.

Where is Escient Pharmaceuticals based?

Escient Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Escient Pharmaceuticals make money?

One revenue line is on record: drug Development and Commercialization.

Who are Escient Pharmaceuticals's main competitors?

Direct peers on record are Novartis, Cara Therapeutics, Allakos Inc., Evommune Inc., Arcutis Biotherapeutics and Dermavant Sciences. Broad incumbents are Regeneron Pharmaceuticals, Sanofi, Incyte Corporation and Galderma.

Does Escient Pharmaceuticals have an API?

No public API is recorded for Escient Pharmaceuticals.

What industry is Escient Pharmaceuticals in?

Escient Pharmaceuticals's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAKAAAH, Mast Cell Disorders Specialty Care. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Segmentation, Major Trends, and Competitive Overview of the G Protein-Coupled Receptors (GPCR) Structure-Based Drug Design MarketThe GPCR structure-based drug design market is projected to reach $4.89 billion by 2030, growing at a 13.0% CAGR, driven by AI-assisted molecular design, precision medicine focus, and expanding applications in oncology and neurology. In May 2024, Incyte Corporation acquired Escient Pharmaceuticals for $750 million to strengthen its pipeline with first-in-class oral GPCR-targeting MRGPR antagonists. In January 2025, Septerna Inc. launched its Native Complex Platform backed by $100 million in Series A funding to advance drug discovery for previously undruggable GPCRs.openPR.comCholestatic Pruritus Therapeutics Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsightDelveInsight released a market research report projecting the Cholestatic Pruritus Therapeutics market in the 7MM (United States, Germany, Spain, Italy, France, United Kingdom, Japan) to grow at a significant compound annual growth rate by 2034. Mirum Pharmaceuticals Inc. initiated a clinical research study on April 2, 2026, evaluating volixibat for treating pruritus associated with Primary Biliary Cholangitis. The market growth is attributed to an increasing patient population and anticipated launch of emerging therapies, with Cara Therapeutics, GlaxoSmithKline, Escient Pharmaceuticals, Mirum Pharmaceuticals, and Albireo identified as leading companies in the space.WikipediaWikipediaIncyte Corporation, an American pharmaceutical company, has executed several strategic acquisitions and partnerships to expand its therapeutic portfolio. Notable moves include the $1.4 billion acquisition of Villaris Therapeutics in 2022 and the $750 million purchase of Escient Pharmaceuticals in 2024, alongside significant licensing deals with Jiangsu Hengrui Medicine and MorphoSys.PartnologyKey Insights into the 2024 Biotech Funding MarketMarket update reports from PitchBook and Stifel Financial Corp. reveal that biopharma venture capital funding reached US$16.6 billion across 411 deals in the first half of 2024, with Q2 2024 hitting US$9.2 billion — the highest quarterly total since early 2022 — signaling renewed sector confidence amid prevailing interest rates. The biotech funding landscape is shifting toward asset-centric approaches where investors favor advanced clinical assets and proven data, with oncology, immunology/infectious disease, and cardiovascular/metabolic disease leading therapeutic funding at US$3.35 billion, US$2.82 billion, and US$1.67 billion respectively. Key exit activity includes Genmab's $1.8 billion acquisition of ProfoundBio and Incyte's $750 million purchase of Escient Pharmaceuticals, while emerging innovation in CRISPR therapy drug delivery and obesity treatments beyond GLP-1 agonists continues attracting substantial investment.American City Business JournalsIncyte CEO Hervé Hoppenot on real estate, M&A and stock buybacksIncyte CEO Hervé Hoppenot discussed the company's real estate acquisition, $750 million Escient Pharmaceuticals deal, and $2 billion stock buyback. He cited a strong internal pipeline with 10-16 product launches planned through 2029 and a commitment to remain independent.Business Wire BlogIncyte Completes Acquisition of Escient PharmaceuticalsIncyte completed its acquisition of Escient Pharmaceuticals for $750 million plus Escient's net cash. The deal adds EP262 and EP547, first-in-class MRGPR antagonists for mast cell-mediated diseases and pruritus. Incyte will accelerate clinical development of these therapies.YahooINCY- Deal for Escient Enhances Outlook, Brings SynergiesIncyte Corp. agreed to acquire Escient Pharmaceuticals for $750 million. The deal adds EP262 and EP547, oral MRGPRX2 and MRGPRX4 antagonists, with expected clinical proof-of-concept in early 2025 and potential US approvals in 2029. INCY expects commercial and R&D synergies across dermatology and autoimmune disease.American City Business JournalsWilmington-based Incyte to acquire Escient Pharmaceuticals for $750MIncyte agreed to acquire Escient Pharmaceuticals for $750 million in an all-cash deal, gaining access to two small-molecule therapeutics for inflammatory disorders. The acquisition is expected to close in Q3 2025, subject to antitrust clearance, with new product launches potentially starting in 2029.Business Wire BlogIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsIncyte agreed to acquire Escient Pharmaceuticals for $750 million plus Escient's net cash, including its MRGPRX2 and MRGPRX4 antagonists EP262 and EP547. The deal is subject to regulatory clearance and is expected to close in the third quarter of 2024.EscientpharmaIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsIncyte has entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Escient Pharmaceuticals for $750 million plus net cash. The transaction includes the acquisition of Escient's pipeline, specifically first-in-class oral MRGPR antagonists EP262 and EP547, which are being developed for inflammatory disorders such as chronic urticaria and pruritus. The deal is subject to regulatory clearance and is anticipated to close in the third quarter of 2024.